Navigation Links
FDA approves Bystolic, a novel beta blocker
Date:12/18/2007

The U.S. Food and Drug Administration (FDA) has approved Bystolic (nebivolol) for the treatment of hypertension, also known as high blood pressure. Hypertension affects approximately 72 million adults in the U.S. and 65 percent of patients diagnosed with hypertension have not reduced their blood pressure to an acceptable range (blood pressure <140/90 mmHg), underscoring the need for additional therapeutic options.

Bystolic, a novel beta blocker, is a once-daily medication that can be used as monotherapy or in combination with other anti-hypertension treatments to reduce blood pressure with a low incidence of traditional beta blocker side effects. Bystolic works differently than many older beta blockers in that it is preferentially beta 1 selective at doses less than or equal to 10 mg, meaning it selectively blocks the effects of adrenaline at the heart. In addition, Bystolic vasodilates or widens and expands - the blood vessels.

Bystolic, marketed in the U.S. by Forest Laboratories, Inc (NYSE: FRX), will be available in pharmacies nationwide in January 2008. For additional information, visit www.Bystolic.com or call 1-800-678-1605.

Hypertension Statistics:

  • The number of people with high blood pressure is expected to reach about 1.6 billion worldwide by 2025

  • Some individuals are at increased risk based on age, race, lifestyle, body mass index/obesity and family history

  • More than half of all Americans aged 60 and older have high blood pressure

  • Men over the age of 45 are at increased risk

  • Women over the age of 55 are at increased risk

  • Hypertension greatly increases the risk of certain health problems such as stroke, heart attack and kidney failure

  • Blacks are at a greater risk for developing hypertension than Caucasians

  • Most patients need two or more classes of hypertension medications to effectively control their condition


'/>"/>

Contact: Maria Dottori
dottorim@fleishman.com
212-453-2429
Fleishman-Hillard, Inc.
Source:Eurekalert

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Chicago, IL (PRWEB) , ... February 11, 2016 ... ... dedicated to the healthcare industry, ranked among the top five firms in the ... Services and HIT Implementation Support and Staffing. KLAS is a research and insights ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new paper ... surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the importance ... for rhinoplasty surgeons when addressing this vital area. , The upper lateral cartilage ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you back from ... poses a question as a challenge for his readers to examine the full ... Being" (published by Partridge Singapore), Clarke explores the subject with more depth, revealing ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Colorado spine ... as one of 334 spine surgeons to know in 2016 . The list ... the field of spine surgery. , Dr. Corenman understands the importance of clinical ...
(Date:2/11/2016)... Little Rock, AR (PRWEB) , ... February 11, 2016 , ... ... Change in their community by announcing a new fundraiser in support of a local ... agency also hopes the campaign will bring awareness to, and rally support for, all ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016   Health 2.0 , the ... health technologies, announced today " 10 Year Global Retrospective ... tech over the past ten years.   ... decade, Health 2.0 has served as the preeminent thought-leader ... with thousands of technologies, companies, innovators, and patient-activists through ...
(Date:2/11/2016)... , Feb. 11, 2016 AAIPharma Services ... of custom manufacturing and development services for the ... fill-finish capabilities and capacity in its ... demand has driven several recent investments. ... had one filling line with small-scale lyophilization. The ...
(Date:2/11/2016)... de 2016  A Proliant Biologicals anuncia, com ... bovina (BSA -- Bovine Serum Albumin ) ... Norte da Nova Zelândia, em Feilding. ... da Proliant nos EUA, localizada em ... dos equipamentos foram feitos de forma a reproduzir ...
Breaking Medicine Technology: